Is Viatris a Great Dividend Stock or Just a Value Trap? [Yahoo! Finance]
Viatris Inc. (VTRS)
Company Research
Source: Yahoo! Finance
The company's medications are in 165 countries and much of its business centers around generic drugs. But while its operations are diverse, this isn't the type of enterprise that screams growth. Chances are, if you're considering Viatris for your portfolio, it's because of its dividend and low valuation. With a 3.9% yield, the healthcare stock offers investors a higher payout than the S&P 500 average of 1.4%. It's also trading at just 4 times its estimated future earnings (based on analyst projections). Those are a couple of big incentives to own the stock. But with its earnings declining significantly last year, is this really a great dividend stock to own, or just a value trap? Operating income fell by more than 50% in 2023 Viatris' latest earnings numbers should have investors a little concerned. Although revenue declined by 5% in 2023, the company also divested of some businesses in order to focus on therapeutic areas that it believes are core parts of its future: ophthalmol
Show less
Read more
Impact Snapshot
Event Time:
VTRS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VTRS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VTRS alerts
High impacting Viatris Inc. news events
Weekly update
A roundup of the hottest topics
VTRS
News
- Inflation Reduction Act: A Bullish Catalyst For Viatris Inc. [Seeking Alpha]Seeking Alpha
- Global Epilepsy Treatment Drugs Market Size To Exceed USD 12.1 Billion By 2033 | CAGR Of 4.36% [Yahoo! Finance]Yahoo! Finance
- Viatris Announces Product Donations To Direct Relief of More Than 7 Million Doses of Medicine To Support Access to Medicine and Healthcare [Yahoo! Finance]Yahoo! Finance
- Viatris to Report First Quarter 2024 Financial Results on May 9, 2024PR Newswire
- Viatris Appoints Corinne Le Goff as Chief Commercial Officer [Yahoo! Finance]Yahoo! Finance
VTRS
Earnings
- 2/28/24 - Miss
VTRS
Sec Filings
- 4/26/24 - Form 10-K/A
- 4/19/24 - Form 4
- 4/19/24 - Form 3
- VTRS's page on the SEC website